Fate Therapeutics (FATE) Stock Price, Quote & News

Latest News on FATE

Apr 14, 2025, 8:00 AM EDT - 12 days ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 2, 2025, 4:01 PM EDT - 24 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mar 5, 2025, 4:01 PM EST - 7 weeks ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 4, 2025, 4:01 PM EST - 7 weeks ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Feb 14, 2025, 4:01 PM EST - 2 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2025, 7:41 PM EST - 2 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Dec 9, 2024, 4:01 PM EST - 4 months ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 5 months ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 5 months ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 20, 2024, 4:34 PM EST - 5 months ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 18, 2024, 8:05 AM EST - 5 months ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 5 months ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 6 months ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 6 months ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 8 months ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 9 months ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

May 29, 2024, 4:01 PM EDT - 11 months ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 1 year ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2023, 12:10 PM EST - 1 year ago

Fate Therapeutics: Getting There, But Perpetually

Nov 8, 2023, 9:12 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 11:37 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

May 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 23, 2023, 1:40 PM EDT - 2 years ago

Fate Therapeutics: The Future Remains Cloudy

May 3, 2023, 8:34 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript

May 3, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

Mar 21, 2023, 5:45 PM EDT - 2 years ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Feb 28, 2023, 10:57 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Call Transcript

Feb 28, 2023, 4:01 PM EST - 2 years ago

Market Cap	146.69M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,366.54%
Debt to Equity Ratio	0.00

Volume	1,237,500
Avg Vol	2,622,502
Day's Range	N/A - N/A
Shares Out	114.60M
Stochastic %K	66%
Beta	2.41
Analysts	Sell
Price Target	$6.86